Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?

Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
The Growing Influence of the Institute of Clinical and… 11/21/2019